Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to earnings of $0.42 per share a year ago.

We have seen 56 institutional investors add shares of $STRO stock to their portfolio, and 78 decrease their positions in their most recent quarter.

Sutro Biopharma, Inc. (NASDAQ:STRO – Get Free Report) has received a consensus recommendation of “Hold” from the nine brokerages that are currently covering the company, Marketbeat reports.

The STRO Companies is a content partner of Bisnow and have worked with our Studio B team to develop creative content and custom offerings. The STRO Companies actively pursue new “value-add” an ...

March 15, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today ...

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...